Corindus Vascular Robotics

Corindus Vascular Robotics is a medical-device company focused on robotic assistance for minimally invasive vascular interventions. The business originated in Israel in 2002, founded by Rafael Beyar, an interventional cardiologist, and Tal Wenderow, who had studied with Beyar at the Technion. Its original concept was to allow physicians to control coronary guidewires and balloon- and stent-delivery catheters remotely rather than manipulating those instruments directly at the patient’s bedside. The company later relocated its headquarters to Waltham, Massachusetts, and developed the CorPath family of systems. The technology places the interventional physician in a protected cockpit from which the physician can manipulate guidewires and balloon or stent catheters. This configuration was designed to support precise device handling while increasing the physical distance between the operator and radiation generated during fluoroscopically guided procedures. Corindus’s system became notable as the first medical device cleared by the United States Food and Drug Administration to let an interventionalist control these types of instruments from an interventional cockpit. Corindus initially concentrated on coronary interventions, where physicians use guidewires and catheter-based balloons or stents to treat narrowed or blocked arteries. The company’s broader strategic direction was to extend robotic assistance across vascular procedures and to obtain additional regulatory clearances. Its principal commercial offering was the CorPath System, later associated with the company’s efforts to expand the capabilities and indications of its robotic platform. The company became a public company in August 2014 and traded on the New York Stock Exchange under the symbol CVRS. During the period when Mark Toland served as chief executive officer and David Long served as chief financial officer, Corindus continued product development and pursued additional FDA clearances. The company’s growth strategy depended on investing in next-generation robotic technology, broadening clinical applications, and increasing adoption of robotic-assisted vascular intervention. In August 2019, Siemens Healthineers announced its intention to acquire Corindus for approximately $1.1 billion. The transaction closed in October 2019 and was described as one of the largest medical-technology acquisitions of that year. Following the transaction, Corindus became part of Siemens Healthineers rather than remaining an independently traded public company. The Corindus name and robotic vascular-intervention technology therefore became associated with Siemens Healthineers’ broader medical-imaging and image-guided-therapy activities. Publicly available reference material identifies the business primarily through its CorPath platform and its role in developing robotic assistance for catheter-based vascular procedures.

Corindus Vascular Robotics began in Israel in 2002 as a robotics venture founded by Rafael Beyar, an interventional cardiologist, and Tal Wenderow, his student at the Technion. The founding idea was to apply robotic control to coronary catheter procedures. In conventional interventions, physicians manipulate guidewires, balloons, and stents directly while standing close to the fluoroscopic imaging field. Corindus sought to move that control into a dedicated cockpit, allowing the physician to operate the instruments remotely and with computerized mechanical assistance. The company subsequently moved its headquarters to Waltham, Massachusetts, and developed the CorPath platform. The platform was designed for interventional cardiology and vascular procedures, with controls for guidewires and balloon- or stent-delivery catheters. Its FDA clearance was historically significant because it made the CorPath System the first medical device authorized to let an interventionalist manipulate these instruments from an interventional cockpit. The product positioned Corindus at the intersection of medical robotics, catheter-based therapy, and image-guided intervention. Corindus’s development path centered on expanding the usefulness of its robotic system beyond its initial coronary application. The company invested in next-generation products and sought further FDA clearances for additional procedural capabilities. These efforts supported a strategy of building a broader vascular robotics platform rather than limiting the business to a single device or procedure type. In August 2014, Corindus entered the public markets and began trading on the New York Stock Exchange under the ticker CVRS. During its public-company period, Mark Toland was identified as chief executive officer and David Long as chief financial officer. Under their leadership, the company continued commercial and regulatory development of its robotic technology. The available reference material emphasizes product development and regulatory expansion but does not provide a complete chronology of every clearance, launch, or management transition. A major turning point came in August 2019, when Siemens Healthineers announced its intention to acquire Corindus for approximately $1.1 billion. The transaction reflected the growing strategic interest in robotic assistance for image-guided and minimally invasive procedures. It closed in October 2019 and was characterized in the reference material as one of the largest medical-technology transactions of 2019. After closing, Corindus ceased to operate as an independently listed company and became part of Siemens Healthineers. Its CorPath technology continued to represent the company’s central contribution to robotic vascular intervention, while its corporate context shifted from a standalone public medical-device company to a Siemens Healthineers business.

• 2019

  Acquisition by Siemens Healthineers completed

  [1]Corindus Vascular Roboticsen.wikipedia.org

  Siemens Healthineers completed its approximately $1.1 billion acquisition of Corindus in October 2019.

• 2014

  New York Stock Exchange listing

  [1]Corindus Vascular Roboticsen.wikipedia.org

  Corindus became publicly traded on the New York Stock Exchange under the ticker CVRS.

• 2002

  Company founded in Israel

  [1]Corindus Vascular Roboticsen.wikipedia.org

  Rafael Beyar and Tal Wenderow founded the company to develop robotic control for coronary guidewires and balloon- and stent-delivery catheters.

• Headquarters moved to Waltham

  [1]Corindus Vascular Roboticsen.wikipedia.org

  The company later relocated its headquarters to Waltham, Massachusetts, where it operated as a United States medical-device company.

• CorPath receives FDA clearance

  [1]Corindus Vascular Roboticsen.wikipedia.org

  The CorPath System became the first medical device cleared by the FDA to allow interventionalists to manipulate guidewires and balloon or stent catheters from an interventional cockpit.

High-end medical technology focused on robotic assistance for minimally invasive vascular and coronary interventions.

• Robotic vascular-intervention system

  CorPath System

  The CorPath System is a robotic platform for catheter-based vascular intervention. It allows an interventional physician to control coronary guidewires and balloon- or stent-delivery catheters from a dedicated cockpit rather than manipulating them directly at the patient’s bedside. The system was developed to support minimally invasive coronary and vascular procedures and became the first FDA-cleared device of its type to provide this cockpit-based control. Corindus subsequently pursued additional clearances and next-generation development for broader procedural use.

• 2019

  Sale to Siemens HealthineersM&A

  Background

  Corindus had continued investing in next-generation vascular robotics and expanding its regulatory clearances, creating the basis for a strategic transaction.

  Action taken

  Siemens Healthineers announced and then completed the acquisition of Corindus for approximately $1.1 billion.

  Aftermath

  Corindus became part of Siemens Healthineers and was no longer an independently listed company.

  announced acquisition value. $1.1 billion (2019)

  Source

• 2014

  Public-market listingStrategy

  Background

  Corindus sought public capital to support development and commercialization of its vascular robotics platform.

  Action taken

  The company listed on the New York Stock Exchange under the ticker CVRS.

  Aftermath

  Corindus operated as a publicly traded medical-device company until its acquisition by Siemens Healthineers in 2019.

  Source

• 2019

  Siemens Healthineers announces planned acquisition of Corindus[1]Corindus Vascular Roboticsen.wikipedia.org

  M&A

  Siemens Healthineers publicly announced an agreement to acquire Corindus for approximately $1.1 billion, bringing the vascular robotics company into the Siemens Healthineers group.

• 2019

  Siemens Healthineers completes acquisition of Corindus[1]Corindus Vascular Roboticsen.wikipedia.org

  M&A

  The acquisition closed in October 2019, ending Corindus’s period as an independently traded public company.

• 2014

  Corindus becomes a public company on the New York Stock Exchange[1]Corindus Vascular Roboticsen.wikipedia.org

  Other

  Corindus completed its public listing and traded on the New York Stock Exchange under the symbol CVRS.

1. 1Corindus Vascular Roboticsen.wikipedia.org
2. 2Corindus Launches technIQ 1 Smart Procedural Automation Series for CorPath GRX Cath lab Robotic Systemdicardiology.com
3. 3Siemens acquires robotic PCI technology for $1.1 billionhealio.com
4. 4Siemens Completes Acquisition of Cath Lab Robotics Vendor Corindusdicardiology.com